Adam Gridley | President And Chief Executive Officer
Histogenics Corporation

Adam Gridley, President And Chief Executive Officer, Histogenics Corporation

Prior to joining Histogenics, Mr. Gridley served in several senior roles of increasing responsibility at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was most recently Senior Vice President of Technical Operations. During his time at Merz, he served as the global site head responsible for a variety of functions, including R&D, Manufacturing, Quality Operations, Finance and IT. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, Inc. a publicly-traded company that was acquired by Merz in 2010. His responsibilities included all business development, investor relations, strategic planning, and R&D functions, and he was part of the leadership team who led the Company’s IPO and subsequent acquisition by Merz.  Mr. Gridley has held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. D and translational initiatives in the life sciences sector, and was recently appointed Managing Director.

Appearances:



Conference Day 1: Thursday 16th May 2019 @ 17:15

Phase III clinical data

last published: 21/Mar/19 09:25 GMT

back to speakers

There are two parts to the World Advanced Therapies & Regenerative Medicine Congress: a conference and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.

TO SPONSOR / EXHIBIT

Erica Baeta 
+44 (0)207 092 1152 
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson 
t/ +44 (0)207 092 1150 
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor 
+44 (0)207 092 1257 
issa.mauthoor@terrapinn.com